October 24, 2016 8:36 PM ET


Company Overview of Five Prime Therapeutics, Inc.

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast grow...

Two Corporate Drive

South San Francisco, CA 94080

United States

Founded in 2001

154 Employees





Key Executives for Five Prime Therapeutics, Inc.

Founder, Chairman, Chief Executive Officer and President
Age: 67
Total Annual Compensation: $525.0K
Chief Operating Officer and Director
Age: 47
Total Annual Compensation: $383.5K
Chief Strategy Officer and Secretary
Age: 45
Total Annual Compensation: $358.5K
Compensation as of Fiscal Year 2015.

Five Prime Therapeutics, Inc. Key Developments

Five Prime Therapeutics, Inc. Initiates Phase 1b Portion of Trial Evaluating the Immunotherapy Combination of Cabiralizumab (Fpa008) and Opdivo (Nivolumab) in Multiple Tumor Types

Five Prime Therapeutics, Inc. announced that it has initiated the Phase 1b portion of the clinical trial evaluating the immunotherapy combination of cabiralizumab (FPA008), Five Prime's investigational monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R), with OPDIVO® (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, in multiple tumor types. Five Prime initiated the Phase 1a/1b trial, which is expected to enroll approximately 280 patients, in September 2015. During Phase 1a, Five Prime evaluated the safety, pharmacokinetics and biomarkers of escalating doses of cabiralizumab as a monotherapy, as well as in combination with the approved 3 mg/kg dose of nivolumab. Five Prime will continue to run the Phase 1b portion of the trial and will evaluate the safety, tolerability and preliminary efficacy of the selected dose of cabiralizumab in combination with nivolumab for the treatment of advanced solid tumors, including but not limited to non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, glioblastoma, renal cell carcinoma and ovarian cancer.

Five Prime Therapeutics, Inc. Promotes Aron M. Knickerbocker to the Position of Chief Operating Officer and its Principal Operating Officer

On September 8, 2016, the Board of Directors of Five Prime Therapeutics, Inc. promoted Aron M. Knickerbocker, FivePrime's previous Chief Business Officer, to the position of Chief Operating Officer and appointed Mr. Knickerbocker as FivePrime's principal operating officer, effective immediately.

Five Prime Therapeutics, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-13-2016 04:40 PM

Five Prime Therapeutics, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-13-2016 04:40 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Lewis T. Williams, Founder, Chairman, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Five Prime Therapeutics, Inc., please visit www.fiveprime.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.